Susanne Wilke

Susanne obtained a dual degree doctorate from the University of Illinois in chemistry and biochemistry and served a post-doctoral fellowship with Prof. Dr. Hruby at the University of Arizona. Susanne obtained her MBA from the Tuck School of Business at Dartmouth.

Susanne joined Neurotrope BioScience as CEO in 2016 after having previously served as an advisor to the company. Located in New York, Neurotrope is focused on developing new therapies for the treatment of neurodegenerative diseases and developmental disorders. 

​

Previously, Susanne was Director of the Life Sciences Group at CrossBridge International, providing advisory services to transatlantic healthcare companies; the firm specializes in cross-border business transactions between Europe and North America. Earlier, Susanne was a healthcare strategy consultant for The Monitor Company, where she worked with large pharmaceutical players on growth opportunities, oncology emerging market strategies, portfolio analysis, brand strategies, and healthcare reform. 

​

Susanne was Director of Global Commercial Assessments, New Products at Forest Labs, where, she performed commercial assessment and due diligence for M&A and in-licensing opportunities in primary care and specialty pharmaceuticals, building on her expertise in drug pricing and reimbursement considerations. 

​

Susanne had an earlier tenure as a Principal at NGN Capital, where she led technical deal due diligence on 17 private equity investments, focused on therapeutic companies, global spin-out opportunities, and medical devices. Before NGN, Susanne was at Schroder Ventures Life Sciences where she served as a Kauffman Fellow focusing on investments in drug products, medical devices, and healthcare service companies. 

​

Susanne started her career with positions at Amgen, Hoffman-LaRoche, and Vertex Pharmaceuticals.

Susanne served her fellowship under Gene Hill at Schroder Ventures (SV Life Sciences) in Boston, MA as a member of Fellows Class 7.